Zacks Investment Research lowered shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a sell rating in a research note released on Wednesday.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other brokerages also recently commented on NBRV. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics and gave the company a buy rating in a research note on Friday, March 16th. Morgan Stanley assumed coverage on shares of Nabriva Therapeutics in a research note on Wednesday, January 17th. They issued an overweight rating and a $10.00 price objective for the company. Finally, ValuEngine downgraded shares of Nabriva Therapeutics from a sell rating to a strong sell rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $16.69.
A number of large investors have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Nabriva Therapeutics in the 4th quarter valued at approximately $5,188,000. Alyeska Investment Group L.P. bought a new position in shares of Nabriva Therapeutics during the third quarter valued at $5,724,000. Prosight Management LP bought a new position in shares of Nabriva Therapeutics during the fourth quarter valued at $2,939,000. Pura Vida Investments LLC bought a new position in shares of Nabriva Therapeutics during the third quarter valued at $3,481,000. Finally, Rubric Capital Management LP bought a new position in shares of Nabriva Therapeutics during the third quarter valued at $2,457,000. 55.59% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers Nabriva Therapeutics (NBRV) to Sell” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3298284/zacks-investment-research-lowers-nabriva-therapeutics-nbrv-to-sell.html.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.